AstraZeneca PLC closed 22.92% short of its 52-week high of £133.88, which the company reached on September 3rd.

The AstraZeneca PLC ADR AZN slid 2.83% to $64.87 Thursday, on what proved to be an all-around poor trading session for the ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p14,200.00. The ...

AstraZeneca Pharmaceuticals LP and a Christian sales specialist have agreed to settle his suit over the company’s failure to ...

AstraZeneca PLC has a one year low of $62.75 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.

If you’re on the fence about investing in Corcept Therapeutics Incorporated or AstraZeneca PLC because you’re not sure how they measure up, it’s important to compare them on a few factors before ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful ...

Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China ...

AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here are the latest forecasts. When investing, your capital is at risk.

(Alliance News) - AstraZeneca PLC on Friday said it will establish a new global strategic research & development centre in Beijing. The Cambridge, England-based pharmaceutical company said it will ...

(Bloomberg) -- AstraZeneca Plc will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just months after the company’s top executive there was ...